A number of novel, IDH-mutant-specific agents are currently under investigation or in the process of development, including IDH inhibitors, which have been approved for the treatment of acute myeloid leukemia, PARP inhibitors, and demethylating agents like decitabine. The gene discussed is IDH1; the disease is acute myeloid leukemia.